BAYN.DE - Bayer Aktiengesellschaft

XETRA - XETRA Delayed price. Currency in EUR
108.50
-1.15 (-1.05%)
At close: 5:35PM CET
Stock chart is not supported by your current browser
Previous close109.65
Open109.60
Bid0.00 x 28400
Ask0.00 x 2100
Day's range108.35 - 110.05
52-week range86.03 - 123.90
Volume1,727,361
Avg. volume1,782,886
Market cap89.617B
BetaN/A
PE ratio (TTM)18.77
EPS (TTM)5.78
Earnings date20 Feb 2018 - 26 Feb 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est120.92
  • Bayer Betting Plants Can Fertilize Themselves
    Bloomberg Video27 days ago

    Bayer Betting Plants Can Fertilize Themselves

    Oct.26 -- Bayer AG is teaming up with Ginkgo Bioworks, a Boston-based biotechnology company, on a record $100-million wager on farming technology. The seeds for bets like these are sewn at the Bayer Lifescience Center in Cambridge, Massachusetts. Bloomberg's Anne Mostue reports.

  • Brazil pushes back decision on Bayer-Monsanto tie-up
    Reuters3 hours ago

    Brazil pushes back decision on Bayer-Monsanto tie-up

    Brazilian antitrust agency Cade on Wednesday extended its deadline to review the takeover of Monsanto Co (MON.N) by Bayer AG (BAYGn.DE) by 90 days to late March, potentially spoiling plans to wrap up the $66 billion (£49.60 billion) tie-up by the end of the year. Bayer and Monsanto declined to comment on the decision. Brazil is Monsanto's biggest market outside of the United States.

  • Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo
    Zacks7 days ago

    Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

    Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.

  • Reuters - UK Focus7 days ago

    EU mergers and takeovers (Nov 15)

    The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- UK oil company BP and holding company Bridas Corp to acquire oil ...

  • Reuters8 days ago

    Bayer hires new blood to stem 'Amazon effect' in consumer health

    German drugmaker Bayer (BAYGn.DE) has hired the head of Nestle's (NESN.S) baby food business to help it reverse a drop in revenue from consumer health brands, which often fail to appeal to buyers on Amazon (AMZN.O) and other online platforms. Bayer has appointed Nestle's Heiko Schipper, 48, to run the Consumer Health division as a group board member from March 1 next year, replacing Erica Mann, Bayer said in a statement on Wednesday. Bayer was caught off guard by the speed of U.S. consumers switching to online stores at the expense of established drugstores.

  • Reuters - UK Focus8 days ago

    Bayer hires new blood to stem 'Amazon effect' in consumer health

    German drugmaker Bayer (Swiss: BAYN-EUR.SW - news) has hired the head of Nestle's baby food business to help it reverse a drop in revenue from consumer health brands, which often fail to appeal to buyers on Amazon and other online platforms. Bayer (IOB: 0P6S.IL - news) has appointed Nestle's Heiko Schipper, 48, to run the Consumer Health division as a group board member from March 1 next year, replacing Erica Mann, Bayer said in a statement on Wednesday.

  • This Cancer Biotech Is Falling On Its $1.55 Billion Bayer Deal
    Investor's Business Daily8 days ago

    This Cancer Biotech Is Falling On Its $1.55 Billion Bayer Deal

    Loxo toppled Tuesday after agreeing to codevelop two cancer therapies with drug firm Bayer.

  • From Bayer to Qualcomm, M&A Gets Costlier in the EU
    Bloomberg11 days ago

    From Bayer to Qualcomm, M&A Gets Costlier in the EU

    If time is money, big M&A is getting a lot costlier in the European Union thanks to a tactic increasingly deployed by the bloc’s merger watchdogs in Brussels.

  • Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up
    Zacks14 days ago

    Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

    Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.

  • Bayer Shows Improved Relative Price Performance; Still Shy Of Benchmark
    Investor's Business Daily21 days ago

    Bayer Shows Improved Relative Price Performance; Still Shy Of Benchmark

    A Relative Strength Rating upgrade for Bayer shows improving technical performance. Will it continue?

  • Bayer, Novartis clash with UK doctors over use of cheap eye drug
    Reuters22 days ago

    Bayer, Novartis clash with UK doctors over use of cheap eye drug

    Bayer (BAYGn.DE) is weighing legal action and Novartis (NOVN.S) has expressed concern at plans by doctors in the north of England to defy official guidance by using a cancer medicine as a cheap eye drug. Doctors from 12 clinical commissioning groups (CCG) plan to make Roche's (ROG.S) cancer therapy Avastin the preferred option for wet age-related macular degeneration (AMD), even though it is not licensed for this use. David Hambleton, head of the South Tyneside CCG, said the policy of using Avastin rather than Bayer's Eylea or Novartis's Lucentis could save the regional National Health Service (NHS) 13.5 million pounds a year.

  • Reuters - UK Focus22 days ago

    Bayer, Novartis clash with UK doctors over use of cheap eye drug

    Bayer (IOB: 0P6S.IL - news) is weighing legal action and Novartis (IOB: 0QLR.IL - news) has expressed concern at plans by doctors in the north of England to defy official guidance by using a cancer medicine as a cheap eye drug. Doctors from 12 clinical commissioning groups (CCG) plan to make Roche's cancer therapy Avastin the preferred option for wet age-related macular degeneration (AMD (Shenzhen: 002623.SZ - news) ), even though it is not licensed for this use. David Hambleton, head of the South Tyneside CCG, said the policy of using Avastin rather than Bayer's Eylea or Novartis's Lucentis could save the regional National Health Service (NHS) 13.5 million pounds ($18 million) a year.

  • Foreign Stock Roundup: Novartis, Bayer, Glaxo, Total Beat on Earnings
    Zacks23 days ago

    Foreign Stock Roundup: Novartis, Bayer, Glaxo, Total Beat on Earnings

    Political developments guided the movement of most non U.S. markets this week.

  • The Zacks Analyst Blog Highlights: RWE AG, Daimler AG, Bayer Aktiengesellschaft and Arkema S.A.
    Zacks24 days ago

    The Zacks Analyst Blog Highlights: RWE AG, Daimler AG, Bayer Aktiengesellschaft and Arkema S.A.

    The Zacks Analyst Blog Highlights: RWE AG, Daimler AG, Bayer Aktiengesellschaft and Arkema S.A.

  • Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Down Y/Y
    Zacks26 days ago

    Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Down Y/Y

    Bayer AG's (BAYRY) core earnings per share from continuing operations beat expectations in the third quarter of 2017 and the company lost de facto control over the Covestro Group at the end of the quarter.

  • The ‘Amazon Effect’ Is Slicing Into Bayer's U.S. Consumer Business
    Bloomberg27 days ago

    The ‘Amazon Effect’ Is Slicing Into Bayer's U.S. Consumer Business

    Bayer AG, the 154-year-old creator of aspirin, has been ambushed by a growing force: online retailers like Amazon.com Inc.

  • Reuters27 days ago

    Bayer - more antitrust asset sales on the cards after BASF deal

    Bayer (BAYGn.DE) said it expected antitrust authorities to make the planned acquisition of Monsanto (MON.N) conditional on more asset sales after agreeing to sell seed and herbicide businesses for 5.9 billion euro (£5.31 billion) to BASF (BASFn.DE). "By no means did the deal that was signed with BASF constitute the totality of antitrust divestitures ... The agencies will render their verdict on what the necessary remedies are. It's probably a first step and somewhat more is to come," Chief Executive Werner Baumann told an analyst call on Thursday after the release of third-quarter results.

  • Reuters27 days ago

    Bayer hints at shrinking cash call for Monsanto takeover funding

    "We will also use the net proceeds from the announced divestiture to BASF to refinance the Monsanto acquisition," Chief Executive Werner Baumann said in prepared remarks published ahead of a conference call for journalists. Bayer has agreed to sell seed and herbicide businesses for 5.9 billion euros ($7 billion) to BASF, which analysts have said was richly priced.

  • Bayer cuts Monsanto deal value to $63.5 billion on revised debt
    Reuters27 days ago

    Bayer cuts Monsanto deal value to $63.5 billion on revised debt

    German drugmaker Bayer (BAYGn.DE) has cut the value of its takeover of Monsanto (MON.N) by $2.5 billion (£1.89 billion), which combined with windfalls from asset sales means it may have to raise less than expected from shareholders. The Monsanto deal is now valued at $63.5 billion including debt, down from an initial $66 billion, because the U.S. seeds giant had lowered its financial liabilities, Bayer's finance chief said on Thursday. The planned acquisition will boost Bayer's agriculture sales to the same level as its core healthcare business, but the move has not been universally popular among shareholders and has led those with a pharma focus in particular to sell out.

  • The Zacks Analyst Blog Highlights: Deutsche Lufthansa, Peugeot, Luxottica, Bayer and Arkema.
    Zacks28 days ago

    The Zacks Analyst Blog Highlights: Deutsche Lufthansa, Peugeot, Luxottica, Bayer and Arkema.

    The Zacks Analyst Blog Highlights: Deutsche Lufthansa, Peugeot, Luxottica, Bayer and Arkema.

  • Bayer books bumper Q3 as Monsanto merger waits in wings
    AFP28 days ago

    Bayer books bumper Q3 as Monsanto merger waits in wings

    German chemicals and pharmaceuticals giant Bayer said group net profit stood at 3.9 billion euros ($4.6 billion) between July and September, more than triple the 1.2 billion euros reported in the same ...

  • EQS Group28 days ago

    Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer

    DGAP-News: Topas Therapeutics GmbH / Key word(s): Change of Personnel26.10.2017 / 09:00 The issuer is solely responsible for the content of this announcement.Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., asChief Development Officer and Chief Medical Officer Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering   To lead Topas' clinical development and regulatory affairsHamburg, 26 October 2017. ...

  • Eurozone Economy Continues to Exude Strength: 5 Great Picks
    Zacks28 days ago

    Eurozone Economy Continues to Exude Strength: 5 Great Picks

    The composite PMI reading remained at a level which indicates that economic activity continues to remain firm across the region.

  • The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene
    Zackslast month

    The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene

    The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene

  • Bayer to Sell Select Business Lines to Close Monsanto Buyout
    Zackslast month

    Bayer to Sell Select Business Lines to Close Monsanto Buyout

    Bayer Aktiengesellschaft (BAYRY) inked a deal to sell selected Crop Science businesses to BASF for EUR 5.9 billion to as a part of its strategy to complete the planned acquisition of Monsanto Co.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes